for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Harpoon Therapeutics Inc

HARP.O

Latest Trade

20.00USD

Change

-0.26(-1.28%)

Volume

70,505

Today's Range

19.41

 - 

20.56

52 Week Range

10.55

 - 

25.23

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
20.26
Open
20.56
Volume
70,505
3M AVG Volume
5.48
Today's High
20.56
Today's Low
19.41
52 Week High
25.23
52 Week Low
10.55
Shares Out (MIL)
32.41
Market Cap (MIL)
667.66
Forward P/E
-10.36
Dividend (Yield %)
--

Next Event

Q1 2021 Harpoon Therapeutics Inc Earnings Release

Latest Developments

More

Harpoon Therapeutics Reports Fourth Quarter And Full Year 2020 Financial Results And Provides Corporate Update

Harpoon Therapeutics Granted Orphan Drug Designation From FDA For Hpn217 For Treatment Of Multiple Myeloma

Harpoon Announces Closing Of Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Harpoon Therapeutics Inc

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct, or TriTAC, platform, the Company is developing a pipeline of T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Its TriTAC product candidate, HPN424, is focused on the treatment of metastatic castration-resistant prostate cancer, or mCRPC.

Industry

Biotechnology & Drugs

Contact Info

131 Oyster Point Blvd Ste 300

SOUTH SAN FRANCISCO, CA

94080-1910

United States

+1.650.4437400

https://www.harpoontx.com/

Executive Leadership

Ronald M. Hunt

Chairman of the Board

Gerald McMahon

President, Chief Executive Officer, Director

Georgia L. Erbez

Chief Financial Officer

Holger Wesche

Chief Scientific Officer

Christopher Whitmore

Vice President - Finance, Secretary

Key Stats

1.38 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-25.650

2019

-2.550

2020

-1.990

2021(E)

-1.977
Price To Earnings (TTM)
--
Price To Sales (TTM)
38.27
Price To Book (MRQ)
9.78
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-35.94
Return on Equity (TTM)
-28.67

Latest News

Latest News

BRIEF-Harpoon Therapeutics Reports Changes To Board Of Directors

* HARPOON THERAPEUTICS ANNOUNCES CHANGES TO BOARD OF DIRECTORS

BRIEF-Harpoon Therapeutics Presents Interim Phase 1 Data From An Ongoing Dose Escalation Trial For The Psma-Targeting Tritac® Hpn424

* HARPOON THERAPEUTICS PRESENTS INTERIM PHASE 1 DATA FROM AN ONGOING DOSE ESCALATION TRIAL FOR THE PSMA-TARGETING TRITAC® HPN424 AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM

BRIEF-Harpoon Therapeutics To Present Interim Clinical Data For Tritac At ASCO20 Virtual Scientific Program

* HARPOON THERAPEUTICS TO PRESENT INTERIM CLINICAL DATA FOR TRITAC® HPN424 AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM Source text for Eikon: Further company coverage:

BRIEF-Harpoon Therapeutics Doses First Patient With HPN217 For Multiple Myeloma

* HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN217, A BCMA TARGETING TRITAC, FOR MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

BRIEF-Harpoon Therapeutics Files For Mixed Shelf Of Up To $250 Million

* HARPOON THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $250.0 MILLION - SEC FILING Source: (http://bit.ly/2w8qzx9) Further company coverage:

BRIEF-Harpoon Therapeutics Reports Q4 Revenue Of $2.2 Mln

* HARPOON THERAPEUTICS REPORTS FOURTH QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up